| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Dominique Shum-Tim | |
| Arghya Paul | |||
| John M Connell | |||
| Divya Murali | |||
| Khalid M Ridwan | |||
| Mohammad T Alrefai | |||
| P2860 | cites work | Efficient and scalable purification of cardiomyocytes from human embryonic and induced pluripotent stem cells by VCAM1 surface expression | Q21135255 |
| Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 | Q21534928 | ||
| Intramyocardial delivery of CD133+ bone marrow cells and coronary artery bypass grafting for chronic ischemic heart disease: safety and efficacy studies | Q79826696 | ||
| Isolation and expansion of adult cardiac stem cells from human and murine heart | Q80837204 | ||
| Intracoronary administration of autologous adipose tissue-derived stem cells improves left ventricular function, perfusion, and remodelling after acute myocardial infarction | Q81435055 | ||
| First experience in humans using adipose tissue-derived regenerative cells in the treatment of patients with ST-segment elevation myocardial infarction | Q83333593 | ||
| Development and evaluation of a perfusion decellularization porcine heart model--generation of 3-dimensional myocardial neoscaffolds | Q83386867 | ||
| Adipose-derived stem cells are an effective cell candidate for treatment of heart failure: an MR imaging study of rat hearts | Q84162391 | ||
| Decellularized tracheal matrix scaffold for tissue engineering | Q84888267 | ||
| Preparation of cardiac extracellular matrix scaffolds by decellularization of human myocardium | Q86560010 | ||
| A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina: design of the RENEW study | Q86853989 | ||
| Adipose-derived regenerative cells in patients with ischemic cardiomyopathy: The PRECISE Trial | Q88127754 | ||
| Biomaterials for the Treatment of Myocardial Infarction | Q22252426 | ||
| Heart Disease and Stroke Statistics--2010 Update: A Report From the American Heart Association | Q22306345 | ||
| Endogenous Wnt/beta-catenin signaling is required for cardiac differentiation in human embryonic stem cells | Q24323226 | ||
| Evidence for cardiomyocyte renewal in humans | Q24594522 | ||
| Tissue-engineered cardiac patch for advanced functional maturation of human ESC-derived cardiomyocytes | Q24623082 | ||
| Growth of engineered human myocardium with mechanical loading and vascular coculture | Q24630666 | ||
| Injectable self-assembling peptide nanofibers create intramyocardial microenvironments for endothelial cells | Q24644294 | ||
| Physiological function and transplantation of scaffold-free and vascularized human cardiac muscle tissue | Q24652369 | ||
| Decellularized matrices for cardiovascular tissue engineering | Q27011803 | ||
| Lentiviral vectors and protocols for creation of stable hESC lines for fluorescent tracking and drug resistance selection of cardiomyocytes | Q27350032 | ||
| Induced regeneration--the progress and promise of direct reprogramming for heart repair | Q27687630 | ||
| Induction of pluripotent stem cells from adult human fibroblasts by defined factors | Q27860967 | ||
| Embryonic stem cell lines derived from human blastocysts | Q27861010 | ||
| Bone marrow cells regenerate infarcted myocardium | Q28210640 | ||
| Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI) | Q28216990 | ||
| Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart | Q28264555 | ||
| The acute and long-term effects of intracoronary Stem cell Transplantation in 191 patients with chronic heARt failure: the STAR-heart study | Q28286170 | ||
| Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population | Q29616533 | ||
| Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines | Q29616799 | ||
| Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial | Q29620043 | ||
| RETRACTED: Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial | Q29620044 | ||
| Adult cardiac stem cells are multipotent and support myocardial regeneration | Q29620122 | ||
| Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts | Q29620480 | ||
| In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes | Q29620599 | ||
| Parthenogenetic stem cells for tissue-engineered heart repair | Q30536576 | ||
| In vitro fabrication of functional three-dimensional tissues with perfusable blood vessels | Q30540002 | ||
| Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction | Q30824170 | ||
| Functional assembly of engineered myocardium by electrical stimulation of cardiac myocytes cultured on scaffolds | Q30846050 | ||
| Impact of decellularization of xenogeneic tissue on extracellular matrix integrity for tissue engineering of heart valves | Q31015644 | ||
| Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial | Q31033745 | ||
| Monitoring of bone marrow cell homing into the infarcted human myocardium | Q31162853 | ||
| Long-term effects of porcine small intestine submucosa on the healing of medial collateral ligament: a functional tissue engineering study | Q33235360 | ||
| Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial | Q33263365 | ||
| Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis | Q33285990 | ||
| Randomized, controlled trial of intramuscular or intracoronary injection of autologous bone marrow cells into scarred myocardium during CABG versus CABG alone | Q33361149 | ||
| Feasibility, safety, and therapeutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a porcine ischemic cardiomyopathy model | Q43659756 | ||
| Fabrication of pulsatile cardiac tissue grafts using a novel 3-dimensional cell sheet manipulation technique and temperature-responsive cell culture surfaces | Q43893196 | ||
| Characterization and enrichment of cardiomyocytes derived from human embryonic stem cells | Q44145594 | ||
| One-year follow-up of feasibility and safety of the first U.S., randomized, controlled study using 3-dimensional guided catheter-based delivery of autologous skeletal myoblasts for ischemic cardiomyopathy (CAuSMIC study). | Q44237365 | ||
| Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure | Q44411377 | ||
| A nanobiohybrid complex of recombinant baculovirus and Tat/DNA nanoparticles for delivery of Ang-1 transgene in myocardial infarction therapy | Q44527379 | ||
| Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes | Q45084863 | ||
| PAMAM dendrimer-baculovirus nanocomplex for microencapsulated adipose stem cell-gene therapy: in vitro and in vivo functional assessment. | Q45880644 | ||
| Favorable effects of the detergent and enzyme extraction method for preparing decellularized bovine pericardium scaffold for tissue engineered heart valves. | Q45977273 | ||
| Collagen matrices enhance survival of transplanted cardiomyoblasts and contribute to functional improvement of ischemic rat hearts. | Q45992110 | ||
| Injectable biopolymers enhance angiogenesis after myocardial infarction. | Q46140198 | ||
| Stepwise solubilization-based antigen removal for xenogeneic scaffold generation in tissue engineering | Q46162034 | ||
| Cardiac patch constructed from human fibroblasts attenuates reduction in cardiac function after acute infarct | Q46332086 | ||
| Fibrin glue alone and skeletal myoblasts in a fibrin scaffold preserve cardiac function after myocardial infarction | Q46599109 | ||
| A synthetic non-degradable polyethylene glycol hydrogel retards adverse post-infarct left ventricular remodeling | Q46626735 | ||
| Tissue regeneration observed in a porous acellular bovine pericardium used to repair a myocardial defect in the right ventricle of a rat model. | Q46695709 | ||
| Glutaraldehyde-fixed bioprosthetic heart valve conduits calcify and fail from xenograft rejection | Q46702378 | ||
| Safety and feasibility of autologous myoblast transplantation in patients with ischemic cardiomyopathy: four-year follow-up | Q46711448 | ||
| Effect of injectable alginate implant on cardiac remodeling and function after recent and old infarcts in rat. | Q46721162 | ||
| Human cord blood cells and myocardial infarction: effect of dose and route of administration on infarct size | Q47245780 | ||
| Hydrogel-based engineered skeletal muscle grafts normalize heart function early after myocardial infarction | Q47412590 | ||
| Ventricular myocytes are not terminally differentiated in the adult mammalian heart | Q47817490 | ||
| Transcoronary transplantation of functionally competent BMCs is associated with a decrease in natriuretic peptide serum levels and improved survival of patients with chronic postinfarction heart failure: results of the TOPCARE-CHD Registry | Q48231288 | ||
| SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells. | Q37104201 | ||
| Subepicardial endothelial cells invade the embryonic ventricle wall to form coronary arteries | Q37141121 | ||
| Cardiac tissue engineering using perfusion bioreactor systems | Q37391209 | ||
| Design of electrical stimulation bioreactors for cardiac tissue engineering | Q37407278 | ||
| Challenges in cardiac tissue engineering | Q37583950 | ||
| Ten years of cord blood transplantation: from bench to bedside | Q37606563 | ||
| Injectable materials for the treatment of myocardial infarction and heart failure: the promise of decellularized matrices | Q37772818 | ||
| Tissue engineering on matrix: future of autologous tissue replacement | Q37833522 | ||
| Whole-organ tissue engineering: decellularization and recellularization of three-dimensional matrix scaffolds | Q37854618 | ||
| Organ engineering based on decellularized matrix scaffolds | Q37868162 | ||
| Stem cell therapy for the treatment of myocardial infarction. | Q37932599 | ||
| Signaling during epicardium and coronary vessel development. | Q37967123 | ||
| Patching the heart: cardiac repair from within and outside | Q38136924 | ||
| Advances in tissue engineering through stem cell-based co-culture | Q38184951 | ||
| Bioengineered baculoviruses as new class of therapeutics using micro and nanotechnologies: principles, prospects and challenges. | Q38185817 | ||
| Stem cell therapy for heart failure | Q38193305 | ||
| Decellularization and recellularization technologies in tissue engineering | Q38210875 | ||
| The cardiac stem cell compartment is indispensable for myocardial cell homeostasis, repair and regeneration in the adult. | Q38212535 | ||
| Intramyocardial bone marrow cell injection for chronic myocardial ischemia: a randomized controlled trial | Q38381605 | ||
| Intracoronary injection of bone marrow-derived mononuclear cells early or late after acute myocardial infarction: effects on global left ventricular function | Q38452784 | ||
| Final results of a phase IIa, randomised, open-label trial to evaluate the percutaneous intramyocardial transplantation of autologous skeletal myoblasts in congestive heart failure patients: the SEISMIC trial | Q39272735 | ||
| Extracellular matrix promotes highly efficient cardiac differentiation of human pluripotent stem cells: the matrix sandwich method | Q39293258 | ||
| The quest for an optimized protocol for whole-heart decellularization: a comparison of three popular and a novel decellularization technique and their diverse effects on crucial extracellular matrix qualities. | Q39547022 | ||
| Perfusion cell seeding on large porous PLA/calcium phosphate composite scaffolds in a perfusion bioreactor system under varying perfusion parameters | Q39651311 | ||
| Pore size variable type I collagen gels and their interaction with glioma cells | Q39709177 | ||
| Non-cardiomyocytes influence the electrophysiological maturation of human embryonic stem cell-derived cardiomyocytes during differentiation | Q39765000 | ||
| Functional improvement of infarcted heart by co-injection of embryonic stem cells with temperature-responsive chitosan hydrogel | Q39908073 | ||
| Preparation of cardiac extracellular matrix from an intact porcine heart | Q39952932 | ||
| Transgenic enrichment of cardiomyocytes from human embryonic stem cells | Q40076187 | ||
| Electromechanical integration of cardiomyocytes derived from human embryonic stem cells. | Q40479961 | ||
| Survival and function of bioengineered cardiac grafts | Q40789498 | ||
| Cardiac fibroblast-derived extracellular matrix (biomatrix) as a model for the studies of cardiac primitive cell biological properties in normal and pathological adult human heart | Q40880502 | ||
| Formation of the coronary vasculature: a brief review | Q40951407 | ||
| Biowire: a platform for maturation of human pluripotent stem cell-derived cardiomyocytes | Q41192534 | ||
| The adult heart responds to increased workload with physiologic hypertrophy, cardiac stem cell activation, and new myocyte formation | Q41812130 | ||
| Heart repair by reprogramming non-myocytes with cardiac transcription factors | Q41859789 | ||
| Naturally derived myocardial matrix as an injectable scaffold for cardiac tissue engineering | Q41969553 | ||
| Design and characterization of an injectable pericardial matrix gel: a potentially autologous scaffold for cardiac tissue engineering | Q42020186 | ||
| Adult c-kit(pos) cardiac stem cells are necessary and sufficient for functional cardiac regeneration and repair. | Q42250849 | ||
| Bioactive baculovirus nanohybrids for stent based rapid vascular re-endothelialization | Q42278869 | ||
| Improved exercise capacity and ischemia 6 and 12 months after transendocardial injection of autologous bone marrow mononuclear cells for ischemic cardiomyopathy | Q42635770 | ||
| Intracoronary administration of cardiac progenitor cells alleviates left ventricular dysfunction in rats with a 30-day-old infarction | Q42644713 | ||
| Stem cell engineering for cardiac tissue regeneration | Q43166729 | ||
| Intracoronary injection of in situ forming alginate hydrogel reverses left ventricular remodeling after myocardial infarction in Swine. | Q43281271 | ||
| Effects of intracoronary injection of mononuclear bone marrow cells on left ventricular function, arrhythmia risk profile, and restenosis after thrombolytic therapy of acute myocardial infarction. | Q33374961 | ||
| Randomized study of mononuclear bone marrow cell transplantation in patients with coronary surgery | Q33385868 | ||
| A pilot trial to assess potential effects of selective intracoronary bone marrow-derived progenitor cell infusion in patients with nonischemic dilated cardiomyopathy: final 1-year results of the transplantation of progenitor cells and functional reg | Q33508959 | ||
| Red blood cell contamination of the final cell product impairs the efficacy of autologous bone marrow mononuclear cell therapy | Q33546217 | ||
| Effects of cell number on teratoma formation by human embryonic stem cells | Q33835956 | ||
| Stem cells in the dog heart are self-renewing, clonogenic, and multipotent and regenerate infarcted myocardium, improving cardiac function | Q33863225 | ||
| Evidence that human cardiac myocytes divide after myocardial infarction | Q33950386 | ||
| The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. | Q34010010 | ||
| Safety and efficacy of an injectable extracellular matrix hydrogel for treating myocardial infarction | Q34035670 | ||
| Antigen removal for the production of biomechanically functional, xenogeneic tissue grafts | Q34039047 | ||
| Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial | Q34074673 | ||
| LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction | Q34090699 | ||
| Injectable graphene oxide/hydrogel-based angiogenic gene delivery system for vasculogenesis and cardiac repair | Q34104323 | ||
| Fabrication of cardiac patch with decellularized porcine myocardial scaffold and bone marrow mononuclear cells | Q34105709 | ||
| Survival and development of neonatal rat cardiomyocytes transplanted into adult myocardium | Q34114690 | ||
| Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming | Q34245487 | ||
| Inefficient reprogramming of fibroblasts into cardiomyocytes using Gata4, Mef2c, and Tbx5 | Q34274633 | ||
| Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial | Q34332467 | ||
| Human embryonic stem cell-derived cardiomyocytes engraft but do not alter cardiac remodeling after chronic infarction in rats | Q34355730 | ||
| Genetically selected cardiomyocytes from differentiating embronic stem cells form stable intracardiac grafts | Q34387398 | ||
| Stem and progenitor cells: origins, phenotypes, lineage commitments, and transdifferentiations | Q34425181 | ||
| Targeted genomic integration of a selectable floxed dual fluorescence reporter in human embryonic stem cells | Q34447692 | ||
| Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial | Q34467911 | ||
| Cardiomyocyte enrichment in differentiating ES cell cultures: strategies and applications. | Q34479212 | ||
| Decellularization of tissues and organs. | Q34499965 | ||
| Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts | Q34508414 | ||
| Stem cell niches in the adult mouse heart | Q34657903 | ||
| Thermoresponsive hydrogels in biomedical applications | Q34690750 | ||
| Engineered cardiac organoid chambers: toward a functional biological model ventricle | Q34760699 | ||
| Mechanical evaluation of decellularized porcine thoracic aorta | Q35001490 | ||
| Cellular cardiomyoplasty--cardiomyocytes, skeletal myoblasts, or stem cells for regenerating myocardium and treatment of heart failure? | Q35131747 | ||
| Cardiac tissue engineering for replacement therapy | Q35184048 | ||
| Decellularized allogeneic heart valves demonstrate self-regeneration potential after a long-term preclinical evaluation | Q35190282 | ||
| Intramyocardial, autologous CD34+ cell therapy for refractory angina | Q35308043 | ||
| Intra-myocardial biomaterial injection therapy in the treatment of heart failure: Materials, outcomes and challenges. | Q35524961 | ||
| Nanowired three-dimensional cardiac patches | Q35528919 | ||
| Developmental stage-specific biphasic roles of Wnt/beta-catenin signaling in cardiomyogenesis and hematopoiesis | Q35544524 | ||
| Engineered heart tissue for regeneration of diseased hearts | Q35617381 | ||
| Safety and efficacy of allogeneic cell therapy in infarcted rats transplanted with mismatched cardiosphere-derived cells | Q35666637 | ||
| The identification of different endothelial cell populations within the mouse proepicardium | Q35745263 | ||
| Xenogeneic extracellular matrix as a scaffold for tissue reconstruction. | Q35781276 | ||
| Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease | Q35804026 | ||
| Biphasic role for Wnt/beta-catenin signaling in cardiac specification in zebrafish and embryonic stem cells | Q35808417 | ||
| Human cardiac stem cells | Q35956924 | ||
| Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. | Q36002268 | ||
| Cells, scaffolds, and molecules for myocardial tissue engineering | Q36020144 | ||
| Application of tissue-engineering principles toward the development of a semilunar heart valve substitute | Q36026430 | ||
| Calcification of tissue heart valve substitutes: progress toward understanding and prevention | Q36056113 | ||
| Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. | Q36079527 | ||
| Custom design of the cardiac microenvironment with biomaterials | Q36186023 | ||
| Cardiac progenitor cells from adult myocardium: Homing, differentiation, and fusion after infarction | Q36349782 | ||
| Bioreactors for tissue engineering: focus on mechanical constraints. A comparative review. | Q36591597 | ||
| Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial | Q36603453 | ||
| Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial | Q36694346 | ||
| Comparison of methods for whole-organ decellularization in tissue engineering of bioartificial organs | Q36768973 | ||
| Bioengineered myocardium derived from induced pluripotent stem cells improves cardiac function and attenuates cardiac remodeling following chronic myocardial infarction in rats | Q36861582 | ||
| Cell-based cardiac pumps and tissue-engineered ventricles | Q36883759 | ||
| Cell sheet engineering for heart tissue repair | Q37002081 | ||
| Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction. | Q50734767 | ||
| Uniaxial and biaxial properties of terminally sterilized porcine urinary bladder matrix scaffolds. | Q50959483 | ||
| Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial. | Q50981942 | ||
| Electromechanical characterization of a tissue-engineered myocardial patch derived from extracellular matrix. | Q51039821 | ||
| Massive mechanical loss of microspheres with direct intramyocardial injection in the beating heart: implications for cellular cardiomyoplasty. | Q51140442 | ||
| The use of extracellular matrix as an inductive scaffold for the partial replacement of functional myocardium. | Q51167242 | ||
| Effects of freezing and cryopreservation on the mechanical properties of arteries. | Q51224763 | ||
| Polysurgery of cell sheet grafts overcomes diffusion limits to produce thick, vascularized myocardial tissues. | Q51281365 | ||
| Extracellular matrix scaffold for cardiac repair. | Q51355899 | ||
| From stem cells to viable autologous semilunar heart valve. | Q51447883 | ||
| Perfusion decellularization of whole organs. | Q53539328 | ||
| Tissue cardiomyoplasty using bioengineered contractile cardiomyocyte sheets to repair damaged myocardium: their integration with recipient myocardium. | Q53643202 | ||
| Regeneration of human infarcted heart muscle by intracoronary autologous bone marrow cell transplantation in chronic coronary artery disease: the IACT Study. | Q53651389 | ||
| Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial | Q56610959 | ||
| Cardiopoietic Stem Cell Therapy in Heart Failure | Q57779306 | ||
| Combined delivery approach of bone marrow mononuclear stem cells early and late after myocardial infarction: the MYSTAR prospective, randomized study | Q58071326 | ||
| Intracoronary infusion of mononuclear cells from bone marrow or peripheral blood compared with standard therapy in patients after acute myocardial infarction treated by primary percutaneous coronary intervention: results of the randomized controlled | Q59260969 | ||
| Regenerating functional myocardium: Improved performance after skeletal myoblast transplantation | Q61776512 | ||
| Endogenous Cardiac Stem Cell Activation by Insulin-Like Growth Factor-1/Hepatocyte Growth Factor Intracoronary Injection Fosters Survival and Regeneration of the Infarcted Pig Heart | Q61865092 | ||
| Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Int | Q61942700 | ||
| Influence of Geometry of Transplanted Tooth and Bone on Transformation of Fibroblasts | Q69280061 | ||
| Cardiomyocyte transplantation improves heart function | Q71476830 | ||
| A novel recovery system for cultured cells using plasma-treated polystyrene dishes grafted with poly(N-isopropylacrylamide) | Q72619370 | ||
| Class I and class II anti-HLA antibodies after implantation of cryopreserved allograft material in pediatric patients | Q73388271 | ||
| Early failure of the tissue engineered porcine heart valve SYNERGRAFT in pediatric patients | Q73580561 | ||
| Does transplantation of cardiomyocytes improve function of infarcted myocardium? | Q73914632 | ||
| Cardiac cytokine expression is upregulated in the acute phase after myocardial infarction. Experimental studies in rats | Q74477478 | ||
| Survey of studies examining mammalian cardiomyocyte DNA synthesis | Q74791661 | ||
| Decrease in culture temperature releases monolayer endothelial cell sheets together with deposited fibronectin matrix from temperature-responsive culture surfaces | Q77733896 | ||
| Taking the death toll after cardiomyocyte grafting: a reminder of the importance of quantitative biology | Q77912830 | ||
| Cardiac muscle tissue engineering: toward an in vitro model for electrophysiological studies | Q78117366 | ||
| Optimal biomaterial for creation of autologous cardiac grafts | Q78299157 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | tissue engineering | Q1540285 |
| P304 | page(s) | 81-101 | |
| P577 | publication date | 2015-05-14 | |
| P1433 | published in | Stem Cells and Cloning: advances and applications | Q15817523 |
| P1476 | title | Cardiac tissue engineering and regeneration using cell-based therapy | |
| P478 | volume | 8 |
| Q64227923 | 3D printing approaches for cardiac tissue engineering and role of immune modulation in tissue regeneration |
| Q92566378 | Cardiac tissue-derived extracellular matrix scaffolds for myocardial repair: advantages and challenges |
| Q92497601 | Cell Printing in Complex Hydrogel Scaffolds |
| Q26764826 | Cell-Assisted Lipotransfer: A Systematic Review of Its Efficacy |
| Q26745543 | Heart Failure: Diagnosis, Management and Utilization |
| Q39368381 | Mesenchymal stromal cells' role in tumor microenvironment: involvement of signaling pathways. |
| Q36311441 | Neuropeptide Y3-36 incorporated into PVAX nanoparticle improves functional blood flow in a murine model of hind limb ischemia |
| Q37581016 | New Trends in Heart Regeneration: A Review |
| Q52560637 | New perspectives: systems medicine in cardiovascular disease. |
| Q36504298 | Reaching out: junctions between cardiac telocytes and cardiac stem cells in culture |
| Q42695888 | Stem Cell Therapy: Healing or Hype? Why Stem Cell Delivery Doesn't Work |
| Q38857890 | Striated muscle function, regeneration, and repair |
Search more.